Jan 29, 2022 | BALTIMORE – Complete Omics Inc, a multi-omics molecular diagnostics company, today announces the publication of a new peer reviewed paper in Science Advances journal, demonstrating the value of targeting antigens derived from human endogenous retroviruses (HERVs) specifically overexpressed by tumor cells for new immunotherapy approaches.
Working with, ErVaccine Technologies, a preclinical-stage biotechnology company, Complete Omics scientists utilized our multi-omics companion diagnostics platform to help enable next-generation therapeutic vaccines and cellular immunotherapies targeting so-called “unconventional” tumor antigens, such as those derived from HERVs. These antigens are shared by different tumor types. Their use would provide a therapeutic solution for a larger number of patients.
This scientific publication outlines results which make it possible to consider triple-negative breast cancer as a first indication, and then to target other pathologies such as ovarian cancer, sarcoma, glioblastoma and acute myeloblastic leukemia as subsequent indications [Ref 1].
“We are very happy to work together with Stéphane and his team on developing this new class of cancer therapeutic targets further into clinical utilizations. Companion diagnostics is a very important multi-omics branch that Complete Omics is working on. We are working together with our collaborators from pharmaceuticals, biotechs, and research institutions to couple our patented multi-omics companion diagnostics platforms with their actionable therapeutic strategies.” explains Dr. Qing Wang, Founder of Complete Omics Inc.
Complete Omics Inc. is specialized in developing multi-omics molecular diagnostics tests for a variety of human diseases and developing companion diagnostic solutions for patients and pharmaceutical companies. Other than our own research, we are also working with dozens of institutional collaborators on a variety of different novel applications using our world-leading multi-omics platforms. A lot more milestones are expected to come true soon in 2022. Stay Tuned.
